Impact of input parameters on the prediction of hepatic plasma clearance using the well-stirred model

Current Drug Metabolism

Volumn 11, Issue 7, 2010, Pages 583-594

  Wan, Hong ^a   Bold, Peter ^a   Larsson, Lars Olof ^a   Ulander, Johan ^a   Peters, Sheila ^a   Löfberg, Boel ^a   Ungell, Anna Lena ^a   Någård, Mats ^a   Llinàs, Antonio ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

Blood to plasma ratio (CB CP); In vitro in vivo extrapolation (IVIVE); In vivo hepatic clearance prediction; Microsomal binding or hepatocyte binding or fum; Plasma protein binding; Well stirred model

Indexed keywords

ALFENTANIL; ALPRAZOLAM; AMITRIPTYLINE; CHLORPROMAZINE; CLOZAPINE; DESIPRAMINE; DEXAMETHASONE; DIAZEPAM; DICLOFENAC; DILTIAZEM; DIPHENHYDRAMINE; DOMPERIDONE; IMIPRAMINE; KETAMINE; KETANSERIN; LANIQUIDAR; LORCAINIDE; METHOXSALEN; MIDAZOLAM; PREDNISONE; PROPAFENONE; QUINIDINE; RISPERIDONE; RITANSERIN; SABELUZOLE; SUFENTANIL; TRIAZOLAM; UNINDEXED DRUG; VERAPAMIL; ZOLPIDEM;

ARTICLE; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DRUG CLEARANCE; EXPERIMENTAL MODEL; FOLLOW UP; HEMATOCRIT; HUMAN; LIVER BLOOD FLOW; LIVER CELL; LIVER CLEARANCE; LIVER MICROSOME; LIVER MICROSOME METABOLISM; NONHUMAN; PLASMA CLEARANCE; PLASMA PROTEIN BINDING; PREDICTION; RETROSPECTIVE STUDY; STIRRED REACTOR; WELL STIRRED MODEL;

ANIMALS; HUMANS; LIVER; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PLASMA; PROTEIN BINDING; RATS;

EID: 77958048377     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920010792927334     Document Type: Article

References (41)

1. Andersson, T. B.; Bredberg, E.; Ericsson, H.; Sjoberg, H. An evaluation of the in vitro metabolism data for predicting the clearance and drug-drug interaction potential of CYP2C9 substrates. Drug Metab. Dispos., 2004, 32, 715-721.
2. Obach, R. S. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab. Dispos., 1999, 27, 1350-1359.
3. Shibata, Y.; Takahashi, H.; Chiba, M.; Ishii, Y. Prediction of hepatic clearance and availability by cryopreserved human hepatocytes: An application of serum incubation method. Drug Metab. Dispos., 2002, 30, 892-896.
4. Jones, H. M.; Houston, J. B. Substrate depletion approach for determining in vitro metabolic clearance: Time dependencies in hepatocyte and microsomal incubations. Drug Metab. Dispos., 2004, 32, 973-982.
5. Riley, R. J.; McGinnity, D. F.; Austin, R. P. A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metab. Dispos., 2005, 33, 1304-1311.
6. Ito, K.; Houston, J. B. Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches. Pharm. Res., 2005, 22, 103-112.
7. Houston, J. B.; Galetin, A. Methods for predicting in vivo pharmacokinetics using data from in vitro assays. Curr. Drug Metab., 2008, 9, 940-951.
8. Stringer, R.; Nicklin, P. L.; Houston, J. B. Reliability of human cryopreserved hepatocytes and liver microsomes as in vitro systems to predict metabolic clearance. Xenobiotica, 2008, 38, 1313-1329.
9. Kilford, P. J.; Stringer, R.; Sohal, B.; Houston, J. B.; Galetin, A. Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes. Drug Metabol. Dispos., 2009, 37, 82-89.
10. Laufer, R.; Paz, O. G.; Di Marco, A.; Bonelli, F.; Monteagudo, E.; Summa, V.; Rowley, M. Quantitative Prediction of Human Clearance Guiding the Development of Raltegravir (MK-0518, Isentress) and Related HIV Integrase Inhibitors. Drug Metabol. Dispos., 2009, 37, 873-883.
11. Masimirembwa, C. M.; Thompson, R.; Andersson, T. B. In vitro high throughput screening of compounds for favorable metabolic properties in drug discovery. Comb. Chem. High Throughput Screen., 2001, 4, 245-263.
12. Gillette, J. R. Factors affecting Drug Metabolism. Ann. NY Acad. Sci., 1971, 179, 43-66.
13. Rowland, M.; Benet, L. Z.; Graham, G. G. Clearance Concepts in pharmacokinetics. J. Pharmacokinet. Biopharm., 1973, 1, 123-136.
14. Wilkinson, G. R.; Shand, D. G. A physiological approach to hepatic drug clearance. Clin. Pharmacol. Ther., 1975, 18, 377-390.
15. Yang, J. S.; Jamei, M.; Yeo, K. R.; Rostami-Hodjegan, A.; Tucker, G. T. Misuse of the well-stirred model of hepatic drug clearance. Drug Metab. Dispos., 2007, 35, 501-502.
16. De Buck, S. S.; Sinha, V. K.; Fenu, L. A.; Gilissen, R. A.; Mackie, C. E.; Nijsen, M. J. The prediction of drug metabolism, tissue distribution, and bioavailability of 50 structurally diverse compounds in rat using mechanism-based absorption, distribution, and metabolism prediction tools. Drug Metab. Dispos., 2007, 35, 649-659.
17. De Buck, S. S.; Sinha, V. K.; Fenu, L. A.; Nijsen, M. J.; Mackie, C. E.; Gilissen, R. Prediction of human pharmacokinetics using physiologically based modeling: A retrospective analysis of 26 clinically tested drugs. Drug Metab. Dispos., 2007, 35, 1766-1780.
18. Barter, Z. E.; Bayliss, M. K.; Beaune, P. H.; Boobis, A. R.; Carlile, D. J.; Edwards, R. J.; Houston, J. B.; Lake, B. G.; Lipscomb, J. C.; Pelkonen, O. R.; Tucker, G. T.; Rostami-Hodjegan, A. Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: Reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr. Drug Metab., 2007, 8, 33-45.
19. Obach, R. S. The importance of nonspecific binding in in vitro matrices, its impact on enzyme kinetic studies of drug metabolism reactions, and implications for in vitro in vivo correlations. Drug Metab. Dispos., 1996, 24, 1047-1049.
20. Nagilla, R.; Frank, K. A.; Jolivette, L. J.; Ward, K. W. Investigation of the utility of published in vitro intrinsic clearance data for prediction of in vivo clearance. J. Pharmacol. Toxicol. Methods, 2006, 53, 106-116.
21. Smith, R.; Jones, R. D. O.; Ballard, P. G.; Griffiths, H. H. Determination of microsome and hepatocyte scaling factors for in vitro/in vivo extrapolation in the rat and dog. Xenobiotica, 2008, 38, 1386-1398.
22. Wilson, Z. E.; Rostami-Hodjegan, A.; Burn, J. L.; Tooley, A.; Boyle, J.; Ellis, S. W.; Tucker, G. T. Inter-individual variability in levels of human microsomal protein and hepatocellularity per gram of liver. Br. J. Clin. Pharmacol., 2003, 56, 433-440.
23. Fukuda, H.; Ohashi, R.; Tsuda-Tsukimoto, M.; Tamai, I. Effect of plasma protein binding on in vitro-in vivo correlation of biliary excretion of drugs evaluated by sandwich-cultured rat hepatocytes. Drug Metab. Dispos., 2008, 36, 1275-1282.
24. Mohutsky, M. A.; Chien, J. Y.; Ring, B. J.; Wrighton, S. A. Predictions of the in vivo clearance of drugs from rate of loss using human liver microsomes for phase I and phase II biotransformations. Pharm. Res., 2006, 23, 654-662.
25. Wan, H.; Rehngren, M. High-throughput screening of protein binding by equilibrium dialysis combined with liquid chromatography and mass spectrometry. J. Chromatogr., 2006, A. 1102, 125-134.
26. Wan, H.; Bergström, F. High-throughput screening of drug-protein binding in drug discovery. J. Liq. Chromatogr. Rel. Technol., 2007, 30, 681-700.
27. Davies, B.; Morris, T. Physiological parameters in laboratory animals and humans. Pharm. Res., 1993, 10, 1093-1095.
28. Morris, J. J.; Bruneau, P. P. Prediction of physicochemical properties. In irtual screening for bioactive molecules; Böhm, H., Schneider, G., Eds.; Wiley-VCH Verlag GmbH: Weinheim, 2000; pp. 33-56.
29. Kochansky, C. J.; McMasters, D. R.; Lu, P.; Koeplinger, K. A.; Kerr, H. H.; Shou, M.; Korzekwa, K. R. Impact of pH on plasma protein binding in equilibrium dialysis. Mol. Pharm., 2008, 5, 438-448.
30. Wan, H.; Holmen, A. G. High throughput screening of physicochemical properties and in vitro ADME profiling in drug discovery. Comb. Chem. High Throughput Screen., 2009, 12, 315-329.
31. Shou, M. G.; Hayashi, M.; Pan, Y.; Xu, Y.; Morrissey, K.; Xu, L.; Skiles, G. L. Modeling, prediction, and in vitro in vivo correlation of CYP3A4 induction. Drug Metab. Dispos., 2008, 36, 2355-2370.
32. Howgate, E. M.; Yeo, K. R.; Proctor, N. J.; Tucker, G. T.; Rostami-Hodjegan, A. Prediction of in vivo drug clearance from in vitro data. I: Impact of inter-individual variability. Xenobiotica, 2006, 36, 473-497. (Pubitemid 43890728)
33. Austin, R. P.; Barton, P.; Cockroft, S. L.; Wenlock, M. C.; Riley, R. J. The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. Drug Metab. Dispos., 2002, 30, 1497-1503.
34. Austin, R. P.; Barton, P.; Mohmed, S.; Riley, R. J. The binding of drugs to hepatocytes and its relationship to physicochemical properties. Drug Metab. Dispos., 2005, 33, 419-425.
35. Kilford, P. J.; Gertz, M.; Houston, J. B.; Galetin, A. Hepatocellular binding of drugs: Correction for unbound fraction in hepatocyte incubations using microsomal binding or drug lipophilicity data. Drug Metab. Dispos., 2008, 36, 1194-1197.
36. Gao, H.; Yao, L. L.; Mathieu, H. W.; Zhang, Y.; Maurer, T. S.; Troutman, M. D.; Scott, D. O.; Ruggeri, R. B.; Lin, J. In silico modeling of nonspecific binding to human liver microsomes. Drug Metab. Dispos., 2008, 36, 2130-2135.
37. Brown, H. S.; Chadwick, A.; Houston, J. B. Use of isolated hepatocyte preparations for cytochrome p450 inhibition studies: comparison with Microsomes for K-i determination. Drug Metab. Dispos., 2007, 35, 2119-2126.
38. Hinderling, P. H. Prediction of absolute bioavailability for drugs using oral and renal clearance following a single oral dose: A critical review [1]. Biopharm. Drug Dispos., 1997, 18, 821-824.
39. Hinderling, P. H. Red blood cells-a neglected compartment in pharmacokinetics and pharmacodynamics. Pharmacol. Rev., 1997, 49, 279-295.
40. Paixao, P.; Gouveia, L. F.; Morais, J. A. G. Prediction of drug distribution within blood. Eur. J. Pharm. Sci., 2009, 36, 544-554.
41. Obach, R. S.; Lombardo, F.; Waters, N. J. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metab. Dispos., 2008, 36, 1385-1405.